Advertisement · 728 × 90
#
Hashtag
#CoreOutcomes
Advertisement · 728 × 90
Measuring what matters: How do we know that we do?

Panel at the 56th Int. Annual Meeting, Society for Psychotherapy Research

The presentations in this panel explore two perspectives on the question which constructs could "matter" when measuring outcomes during and at the end of psychological therapies: (i) using conceptual as well as empirical approaches to identify content that captures relevant variation among patients; and (ii) by engaging with stakeholders (including and foremost patients) to identify which constructs provide meaningful or valued information in a given setting.

The first presentation reports on a project that uses empirical methods to develop an ontology for depression measurement. An ontology is a formalised representation of domain knowledge, supporting the comparison and integration of the content of measurement tools. The second presentation focuses on using idiographic methods to identify core elements that matter quantitatively for individual PTSD patients and their trajectories, assimilating principles of clinical case formulations and theoretical models into empirical assessment. The third presentation switches the panel toward the question of meaningful measures. It discusses theoretical frameworks to assess psychotherapy outcomes beyond symptoms, and methods to find agreement on such outcomes. The final talk will present qualitative analyses based on the process evaluation embedded in a multi-centre trial, focusing on the context, mechanisms, and outcomes of the trialled intervention that are relevant for patients. 

All presentations are concerned with how we identify and measure outcomes that matter and they stress that this requires considering different voices, values, and evidence. Since the presentations cover different methodologies and application contexts, the panel encourages attendees to discuss what we perceive as "valid" assessments from this perspective.

[titles of individual presentations follow in the posts below]

Measuring what matters: How do we know that we do? Panel at the 56th Int. Annual Meeting, Society for Psychotherapy Research The presentations in this panel explore two perspectives on the question which constructs could "matter" when measuring outcomes during and at the end of psychological therapies: (i) using conceptual as well as empirical approaches to identify content that captures relevant variation among patients; and (ii) by engaging with stakeholders (including and foremost patients) to identify which constructs provide meaningful or valued information in a given setting. The first presentation reports on a project that uses empirical methods to develop an ontology for depression measurement. An ontology is a formalised representation of domain knowledge, supporting the comparison and integration of the content of measurement tools. The second presentation focuses on using idiographic methods to identify core elements that matter quantitatively for individual PTSD patients and their trajectories, assimilating principles of clinical case formulations and theoretical models into empirical assessment. The third presentation switches the panel toward the question of meaningful measures. It discusses theoretical frameworks to assess psychotherapy outcomes beyond symptoms, and methods to find agreement on such outcomes. The final talk will present qualitative analyses based on the process evaluation embedded in a multi-centre trial, focusing on the context, mechanisms, and outcomes of the trialled intervention that are relevant for patients. All presentations are concerned with how we identify and measure outcomes that matter and they stress that this requires considering different voices, values, and evidence. Since the presentations cover different methodologies and application contexts, the panel encourages attendees to discuss what we perceive as "valid" assessments from this perspective. [titles of individual presentations follow in the posts below]

In a week's time #SPRKrakow2025 will be over already.

I am grateful to my colleagues for joining me for the panel
"Measuring what matters: How do we know that we do?"

#PsychotherapyResearch #Measurement #HRQOL #CoreOutcomes #DundeeUni
@paperbag1.bsky.social

8 0 1 0
Preview
Victoria Gabb - Blog – Learning from experience to develop MCI Core Outcomes In this blog Victoria Gabb shares her second update on developing a core outcome set for mild cognitive impairment research in her latest blog post.

✨ Collaboration at its best! Victoria Gabb is working with patients, caregivers & clinicians to redefine outcomes in #MCI research. Check out her latest blog post (the narrated version in our blogs podcast)! 🤝📘 #CoreOutcomes

pod.fo/e/2827e6

6 0 0 0

The Q&A of Session#2 #MWMsymposium brings up questions around standardisation and #CommonMeasures.

Standardisation is highly desirable for research efforts and practice implementation. But the relevant indicators and their meaning differ across countries, if not even regions.

#CoreOutcomes #ISOQOL

0 0 0 0
Post image

This week's edition of AI helps me to write a #FakeAbstract in response to ludicrous #conference invites has #ChatGPT 3.5 meet " #Nanomaterials #Conference 2024 "

If interested in the work they "contacted" me about:


#CoreOutcomes #HRQL #GlobalHealth

0 0 0 0
Screenshot of a part of an invitation email to contribute to a conference and my ChatGPT prompt and abstract, in part presented here:

My prompt: "Please write a 350 word abstract on how the development of a core outcome set for multimorbidity trials in low- and middle-income countries can contribute to the field of advanced nanomaterials and nanotechnology."
The establishment of a core outcome set (COS) for multimorbidity trials in low- and middle-income countries (LMICs) holds significant implications for the advancement of nanomaterials and nanotechnology. Multimorbidity, the coexistence of two or more chronic health conditions within an individual, presents complex challenges in healthcare delivery and management, particularly in resource-constrained settings. This abstract elucidates the potential synergies between the development of a COS for multimorbidity trials in LMICs and the field of advanced nanomaterials and nanotechnology.

Screenshot of a part of an invitation email to contribute to a conference and my ChatGPT prompt and abstract, in part presented here: My prompt: "Please write a 350 word abstract on how the development of a core outcome set for multimorbidity trials in low- and middle-income countries can contribute to the field of advanced nanomaterials and nanotechnology." The establishment of a core outcome set (COS) for multimorbidity trials in low- and middle-income countries (LMICs) holds significant implications for the advancement of nanomaterials and nanotechnology. Multimorbidity, the coexistence of two or more chronic health conditions within an individual, presents complex challenges in healthcare delivery and management, particularly in resource-constrained settings. This abstract elucidates the potential synergies between the development of a COS for multimorbidity trials in LMICs and the field of advanced nanomaterials and nanotechnology.

This week's edition of AI helps me to write a #FakeAbstract in response to ludicrous #conference invites has #ChatGPT 3.5 meet " #Nanomaterials #Conference 2024 "

In case you are interested in the work they "contacted" me about:
www.medrxiv.org/content/10.1...

#CoreOutcomes #HRQL #GlobalHealth

0 0 0 0

Second installment of @ISOQOL "Measuring What Matters"


Session III underway:
Stakeholder Perspectives on Core Outcome Sets

First up: @SallyOkun on
"Exploring Patient-Informed Principles"

#CoreOutcomes #Psychometrics #PatientCentered

0 0 0 0